Filana Therapeutics (FLNA) Cash from Financing Activities (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Cash from Financing Activities of -$16000.0 for Q2 2026, up 68.63% quarter-over-quarter from -$51000.0 in Q1 2026.
Filana Therapeutics (FLNA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Filana Therapeutics' Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$16000.0 for Q2 2026.
- In Q2 2026, Cash from Financing Activities changed N/A year-over-year to -$16000.0; the TTM figure through Jun 2026 stood at -$396000.0 (down 139.29% YoY), while the FY2025 annual figure was -$239000.0, down 100.19% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at -$16000.0, up from -$51000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $101.4 million in Q2 2024, with the low at -$329000.0 in Q4 2025.
- The 5-year median for Cash from Financing Activities is $211000.0 (2022), against an average of $11.6 million.
- The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities surged 34525.0% in 2024, then slumped 156.67% in 2026.
- Filana Therapeutics' Cash from Financing Activities stood at $47.3 million in 2022, then sank by 97.59% to $1.1 million in 2023, then declined by 19.69% to $918000.0 in 2024, then sank by 135.84% to -$329000.0 in 2025, then jumped by 95.14% to -$16000.0 in 2026.
- Business Quant data shows FLNA's Cash from Financing Activities at -$16000.0 in Q2 2026, -$51000.0 in Q1 2026, and -$329000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | -16,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16,000.00 |
| Jun 30, 2026 | -16,000.00 |
| Mar 31, 2026 | -51,000.00 |
| Mar 31, 2026 | -51,000.00 |
| Dec 31, 2025 | -329,000.00 |
| Dec 31, 2025 | -329,000.00 |
| Mar 31, 2025 | 90,000.00 |
| Mar 31, 2025 | 90,000.00 |
| Dec 31, 2024 | 918,000.00 |
| Dec 31, 2024 | 918,000.00 |
| Jun 30, 2024 | 101.39 Mn |
| Jun 30, 2024 | 101.39 Mn |
| Mar 31, 2024 | 22.16 Mn |
| Mar 31, 2024 | 22.16 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 464,000.00 |
| Sep 30, 2023 | 464,000.00 |
| Jun 30, 2023 | 889,000.00 |
| Jun 30, 2023 | 889,000.00 |